Ignite Creation Date:
2025-12-24 @ 12:47 PM
Ignite Modification Date:
2025-12-27 @ 10:19 PM
Study NCT ID:
NCT06081361
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-01
First Post:
2023-09-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014397', 'term': 'Tuberculosis, Pulmonary'}, {'id': 'D014376', 'term': 'Tuberculosis'}], 'ancestors': [{'id': 'D009164', 'term': 'Mycobacterium Infections'}, {'id': 'D000193', 'term': 'Actinomycetales Infections'}, {'id': 'D016908', 'term': 'Gram-Positive Bacterial Infections'}, {'id': 'D001424', 'term': 'Bacterial Infections'}, {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C493870', 'term': 'bedaquiline'}, {'id': 'C516022', 'term': 'OPC-67683'}, {'id': 'C000590780', 'term': 'contezolid'}, {'id': 'D064704', 'term': 'Levofloxacin'}, {'id': 'D000077266', 'term': 'Moxifloxacin'}, {'id': 'D002991', 'term': 'Clofazimine'}, {'id': 'D000069349', 'term': 'Linezolid'}, {'id': 'D003523', 'term': 'Cycloserine'}, {'id': 'D011515', 'term': 'Prothionamide'}, {'id': 'D011718', 'term': 'Pyrazinamide'}, {'id': 'D010131', 'term': 'Aminosalicylic Acid'}, {'id': 'D004977', 'term': 'Ethambutol'}], 'ancestors': [{'id': 'D015242', 'term': 'Ofloxacin'}, {'id': 'D024841', 'term': 'Fluoroquinolones'}, {'id': 'D042462', 'term': '4-Quinolones'}, {'id': 'D015363', 'term': 'Quinolones'}, {'id': 'D011804', 'term': 'Quinolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010619', 'term': 'Phenazines'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}, {'id': 'D000081', 'term': 'Acetamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000085', 'term': 'Acetates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D023303', 'term': 'Oxazolidinones'}, {'id': 'D010080', 'term': 'Oxazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D007555', 'term': 'Isoxazoles'}, {'id': 'D012694', 'term': 'Serine'}, {'id': 'D021542', 'term': 'Amino Acids, Neutral'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D007539', 'term': 'Isonicotinic Acids'}, {'id': 'D000147', 'term': 'Acids, Heterocyclic'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D011719', 'term': 'Pyrazines'}, {'id': 'D062366', 'term': 'para-Aminobenzoates'}, {'id': 'D062365', 'term': 'Aminobenzoates'}, {'id': 'D001565', 'term': 'Benzoates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D000636', 'term': 'Aminosalicylic Acids'}, {'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D006880', 'term': 'Hydroxy Acids'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D005029', 'term': 'Ethylenediamines'}, {'id': 'D003959', 'term': 'Diamines'}, {'id': 'D011073', 'term': 'Polyamines'}, {'id': 'D000588', 'term': 'Amines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 186}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-12-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-03', 'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-03-26', 'studyFirstSubmitDate': '2023-09-27', 'studyFirstSubmitQcDate': '2023-10-11', 'lastUpdatePostDateStruct': {'date': '2025-04-01', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-10-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-10-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Contezolid plasma concentration', 'timeFrame': '7d±3d after the first dose of contezolid', 'description': 'To build the population PK model of contezolid with steady-state plasma concentration, measured by blood samples taken at four time points around one administration: ≤15min before and 1h±15min, 2h±15min, 3h±15min after. The index adiministration should be in 7d±3d after the first dose of contezolid.'}], 'primaryOutcomes': [{'measure': 'Favourable outcome rate at 24 months after randomization', 'timeFrame': 'from randomization to 24 months after', 'description': "The proportion of participants with a favourable outcome. A participant's outcome will be classified as favourable if their last two sputum culture results are negative unless they have previously been classified as unfavourable. These two cultures must be taken on separate visits (with ≥28d interval); the latest of which not being earlier than month 23 from randomization."}], 'secondaryOutcomes': [{'measure': 'Unfavourable outcome rate at 24 months after randomization', 'timeFrame': 'from randomization to 24 months after', 'description': 'Including\n\n1. Death;\n2. Treatment failure\n3. Lost-to-follow-up\n4. Treatment Discontinuation\n5. Ttreatment prolonging\n6. Still on treatment at the end of follow up\n7. Recurrence'}, {'measure': 'Time to culture conversion', 'timeFrame': 'from randomization to 24 months after', 'description': 'Time from treatment initiation to first negative result in sputum culture confirmed by two consecutive cultures with an interval of ≥28d'}, {'measure': 'Grade 3 or higher adverse event rate', 'timeFrame': 'from randomization to 24 months after', 'description': 'Proportion of participants experiencing at least one grade 3 or higher adverse event, or serious adverse event defined by the Division of AIDS severity criteria for adverse events'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['tuberculosis', 'Rifampicin-resistant', 'short regimen', 'contezolid', 'delamanid'], 'conditions': ['Pulmonary Tuberculosis', 'Rifampicin-resistant Tuberculosis']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to compare the efficacy and safety of a Contezolid and Delamanid-Containing short regimen to standard longer regimen in Rifampicin-resistant pulmonary tuberculosis (RR-TB). The main questions it aims to answer are:\n\n* Is the efficacy of short regimen non-inferior to standard regimen?\n* Is the short regimen safe enough to replace the standard regimen?\n\nParticipants will:\n\n* Be given with either short or standard regimen for RR-TB treatment\n* Be asked to complete the scheduled visit as planned.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion criteria:\n\n1. Age ≥18y and \\<70y when signing informed consent;\n2. Initial or re-treatment for pulmonary tuberculosis with:\n\n1\\) MTB positive in sputum or bronchoalveolar lavage fluid culture at or within 3 months before screening, or MTB positive in molecular test at or within 3 months before screening, and; 2) recorded Rifampicin-resistance at or before screening; 3. Imaging (Chest X-ray or CT scan) proved pulmonary tuberculosis within 1 year before screening; 4. Never used BDQ, DLM or CZD, or the accumulative duration of any of the treatment is not more than 2 weeks 5. For women in childbearing age, negative in pregnancy test and effective contraceptive measures throughout study is required; 6. For men, effective contraceptive measures is required; 7. Willing to participate the study and sign informed consent.\n\nExclusion criteria:\n\n1. The participant will be excluded by investigator based on the medical history or concomitant diseases such as serious metabolic disease, cardiovascular disease, hepatobiliary disease, renal disease, autoimmune disease, neuropsychiatric disorders, hematological disease, malignant neoplastic disease and so on; or the study will have negative impact on the well-being of the participant, or the participant is considered unable to complete the evaluation by investigator;\n2. History of alcohol or drug abuse that the study is considered have negative impact on the well-being of the participant by investigator;\n3. HIV positive;\n4. Chronic hepatitis with HBsAg, HBeAg and anti-HBC antibody positive, or HBV-DNA\\>1000 CPs/mL with rising ALT/AST;\n5. Allergic to or known hypersensitive to any of study drugs;\n6. Extensive (or advanced) pulmonary TB disease: presence of bilateral cavitary disease or extensive parenchymal damage on chest radiography;\n7. Hematogenous disseminated pulmonary tuberculosis and serious extrapulmonary tuberculosis (such as tuberculosis in digestive system, urogenital system, osteoarticular tuberculosis, tuberculous meningitis);\n8. With any of following risk factors for cardiovascular disease: 1) history of arrhythmia and on consequential treatment; 2) QTcF\\>500ms on ECG; 3) history of ventricular arrhythmia; 4) torsade de pointe with heart failure, hypokalemia or familial long Q-T syndrome; 5) other possible risk factor for arrythmia;\n9. Previous or current optic nerve disorder that may progress or deteriorate during the study by investigator's consideration;\n10. Was enrolled within 2 months before screening, or currently in other studies; except for those who participating observational study or in the post-treatment period;\n11. Being considered unlikely to survive for more than 6 months by investigator;\n12. BMI \\< 17kg/m2\n13. May need surgical procedures based on the evaluation of pulmonary lesions;\n14. May continuous use prohibited concomitant medications that is considered not suitable for the study by investigator;\n15. Positive in pregnancy test or known pregnancy, breastfeeding, or plan to become pregnant during or within 6 months after the study treatment;\n16. Abnormal laboratory test results: 1) Plasma potassium lower than lower limit of normal (LLN); 2) Hb \\< 8.0 g/dL； 3) platelet count \\<75,000/mm3； 4) WBC count\\<3000/mm3； 5）AST/ALT \\>3×ULN； 6）creatinine\\>2×ULN；7）total bilirubin\\>2×ULN, or \\>1.5×ULN，with abnormal AST or ALT; 8) Albumin \\< 30g/L"}, 'identificationModule': {'nctId': 'NCT06081361', 'acronym': 'INSPIRE-CODA', 'briefTitle': 'Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort', 'organization': {'class': 'OTHER', 'fullName': 'Beijing Chest Hospital'}, 'officialTitle': 'A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis', 'orgStudyIdInfo': {'id': 'BJCH-202301'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Short-Term Regimen', 'description': 'Intervention will be determined based on Fluoroquinolones(FQs) resistance.\n\n* For those sensitive to FQs: BDQ DLM CZD LFX(MFX) for 6 months\n* For those resistant to FQs: BDQ DLM CZD CFZ for 6 months', 'interventionNames': ['Drug: Bedaquiline', 'Drug: Delamanid', 'Drug: Contezolid', 'Drug: Levofloxacin', 'Drug: Moxifloxacin', 'Drug: Clofazimine']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Standard Regimen', 'description': 'Intervention will be determined based on Fluoroquinolones(FQs) resistance.\n\n* For those sensitive to FQs: BDQ LZD LFX(MFX) CS CFZ regimen for 6 months, then LFX(MFX) CS CFZ for 12 months\n* For those resistant to FQs: LFX(MFX) will be replaced by Pto, PZA, PAS or EMB', 'interventionNames': ['Drug: Bedaquiline', 'Drug: Levofloxacin', 'Drug: Moxifloxacin', 'Drug: Clofazimine', 'Drug: Linezolid', 'Drug: Cycloserine', 'Drug: Prothionamide', 'Drug: Pyrazinamide', 'Drug: Para-Aminosalicylic Acid', 'Drug: Ethambutol']}], 'interventions': [{'name': 'Bedaquiline', 'type': 'DRUG', 'otherNames': ['BDQ'], 'description': 'Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week', 'armGroupLabels': ['Short-Term Regimen', 'Standard Regimen']}, {'name': 'Delamanid', 'type': 'DRUG', 'otherNames': ['DLM'], 'description': 'Oral, 100mg bid', 'armGroupLabels': ['Short-Term Regimen']}, {'name': 'Contezolid', 'type': 'DRUG', 'otherNames': ['CZD'], 'description': 'Oral, 800mg bid', 'armGroupLabels': ['Short-Term Regimen']}, {'name': 'Levofloxacin', 'type': 'DRUG', 'otherNames': ['LFX'], 'description': 'Oral, 400mg qd for weight \\<50kg, 600-750mg qd for weight ≥50kg', 'armGroupLabels': ['Short-Term Regimen', 'Standard Regimen']}, {'name': 'Moxifloxacin', 'type': 'DRUG', 'otherNames': ['MFX'], 'description': 'Oral, 400mg qd', 'armGroupLabels': ['Short-Term Regimen', 'Standard Regimen']}, {'name': 'Clofazimine', 'type': 'DRUG', 'otherNames': ['CFZ'], 'description': 'Oral, 100mg qd', 'armGroupLabels': ['Short-Term Regimen', 'Standard Regimen']}, {'name': 'Linezolid', 'type': 'DRUG', 'otherNames': ['LZD'], 'description': 'Oral, 600mg qd', 'armGroupLabels': ['Standard Regimen']}, {'name': 'Cycloserine', 'type': 'DRUG', 'otherNames': ['CS'], 'description': 'Oral, 250mg bid', 'armGroupLabels': ['Standard Regimen']}, {'name': 'Prothionamide', 'type': 'DRUG', 'otherNames': ['Pto'], 'description': 'Oral, 600mg qd for weight \\<50kg, 600-800mg qd for weight ≥50kg', 'armGroupLabels': ['Standard Regimen']}, {'name': 'Pyrazinamide', 'type': 'DRUG', 'otherNames': ['PZA'], 'description': 'Oral, 1500mg qd for weight \\<50kg, 1750mg qd for weight ≥50kg', 'armGroupLabels': ['Standard Regimen']}, {'name': 'Para-Aminosalicylic Acid', 'type': 'DRUG', 'otherNames': ['PAS'], 'description': '8000mg qd for weight \\<50kg, 10000mg qd for weight ≥50kg', 'armGroupLabels': ['Standard Regimen']}, {'name': 'Ethambutol', 'type': 'DRUG', 'otherNames': ['EMB'], 'description': '750mg qd for weight \\<50kg, 1000mg qd for weight ≥50kg', 'armGroupLabels': ['Standard Regimen']}]}, 'contactsLocationsModule': {'locations': [{'zip': '101149', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Beijing Chest Hospital affiliated to Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Changsha', 'state': 'China', 'country': 'China', 'facility': 'Changsha Central Hospital', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'city': 'Hefei', 'state': 'China', 'country': 'China', 'facility': 'Anhui Chest Hospital', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'city': 'Jiamusi', 'state': 'China', 'country': 'China', 'facility': 'Jiamusi Tumor Hospital', 'geoPoint': {'lat': 46.79711, 'lon': 130.31118}}, {'city': 'Shandong', 'state': 'China', 'country': 'China', 'facility': 'Shandong public health clinical center', 'geoPoint': {'lat': 40.28464, 'lon': 120.48412}}, {'city': "Xi'an", 'state': 'China', 'country': 'China', 'facility': "Xi'an Chest Hospital", 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'city': 'Xinxiang', 'state': 'China', 'country': 'China', 'facility': 'The First Affiliated Hospital of Xinxiang Medical University', 'geoPoint': {'lat': 35.19033, 'lon': 113.80151}}, {'zip': '050000', 'city': 'Shijiazhuang', 'state': 'Hebei', 'country': 'China', 'facility': 'Hebei Chest Hospital', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'zip': '150000', 'city': 'Harbin', 'state': 'Heilongjiang', 'country': 'China', 'facility': 'Harbin Chest Hospital', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'city': 'Hulunbuir', 'state': 'Inner Mongolia', 'country': 'China', 'facility': 'Infectious Disease Hospital of Hulunbuir', 'geoPoint': {'lat': 49.21141, 'lon': 119.75582}}, {'zip': '266000', 'city': 'Qingdao', 'state': 'Shandong', 'country': 'China', 'facility': 'Qingdao Chest Hospital', 'geoPoint': {'lat': 36.06488, 'lon': 120.38042}}, {'zip': '030000', 'city': 'Taiyuan', 'state': 'Shanxi', 'country': 'China', 'facility': "Taiyuan Fourth People's Hospital", 'geoPoint': {'lat': 37.86944, 'lon': 112.56028}}, {'city': 'Beijing', 'country': 'China', 'facility': 'The 8th Medical Center of Chinese Pla General Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Changsha', 'country': 'China', 'facility': 'Hunan Province Chest Hospital', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'city': 'Chongqing', 'country': 'China', 'facility': 'Chongqing Public Heath Treatment Center', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'city': 'Dalian', 'country': 'China', 'facility': 'Dalian Public Health Center', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'city': 'Fuzhou', 'country': 'China', 'facility': 'Fuzhou Pulmonary Hospital of Fujian', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'city': 'Guangzhou', 'country': 'China', 'facility': 'Guangzhou Chest Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Haerbin', 'country': 'China', 'facility': 'Heilongjiang Province center for tuberculosis Control and Prevention'}, {'city': 'Haikou', 'country': 'China', 'facility': 'Second Affiliated Hospital of Hainan Medical University', 'geoPoint': {'lat': 20.03421, 'lon': 110.34651}}, {'city': 'Hangzhou', 'country': 'China', 'facility': 'Hangzhou Red Cross Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'city': 'Hohhot', 'country': 'China', 'facility': "Second People's Hospital of Hohhot", 'geoPoint': {'lat': 40.81056, 'lon': 111.65222}}, {'city': 'Jiamusi', 'country': 'China', 'facility': 'Jiamusi Infectious Disease Hospital', 'geoPoint': {'lat': 46.79711, 'lon': 130.31118}}, {'city': 'Jilin', 'country': 'China', 'facility': 'Jilin Tuberculosis Hospital', 'geoPoint': {'lat': 43.84652, 'lon': 126.5608}}, {'city': 'Linyi', 'country': 'China', 'facility': "People's Hospital of Linyi", 'geoPoint': {'lat': 35.06306, 'lon': 118.34278}}, {'city': 'Nanjing', 'country': 'China', 'facility': 'Second Hospital of Nanjing', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'city': 'Nanning', 'country': 'China', 'facility': "Fourth People's Hospital of Nanning", 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'city': 'Nanning', 'country': 'China', 'facility': 'Guangxi Chest Hospital', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'city': 'Shanghai', 'country': 'China', 'facility': 'National Medical Center for Infectious Disease', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shaoxing', 'country': 'China', 'facility': 'Affiliated Hospital of Shaoxing University', 'geoPoint': {'lat': 30.00237, 'lon': 120.57864}}, {'city': 'Shenyang', 'country': 'China', 'facility': 'Shenyang Chest Hospital', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'city': 'Shijiazhuang', 'country': 'China', 'facility': 'Shijiazhuang Fifth Hospital', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'city': 'Tianjin', 'country': 'China', 'facility': 'Tianjin Haihe Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'city': 'Ürümqi', 'country': 'China', 'facility': 'The 8th Affiliated Hospital of Xinjiang Medical University', 'geoPoint': {'lat': 43.80096, 'lon': 87.60046}}, {'city': 'Weifang', 'country': 'China', 'facility': "Second People's Hospital of Weifang", 'geoPoint': {'lat': 36.71, 'lon': 119.10194}}, {'city': 'Wuhan', 'country': 'China', 'facility': 'Wuhan Institute For Tuberculosis Control', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'city': 'Xiamen', 'country': 'China', 'facility': 'First Affiliated Hospital of Xiamen Medical University', 'geoPoint': {'lat': 24.47979, 'lon': 118.08187}}, {'city': 'Zhengzhou', 'country': 'China', 'facility': 'Henan Provincial Chest Hospital', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'city': 'Zunyi', 'country': 'China', 'facility': 'Affiliated Hospital of Zunyi Medical University', 'geoPoint': {'lat': 27.68667, 'lon': 106.90722}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Beijing Chest Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Medical Center for Infectious Diseases', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Chu naihui', 'investigatorAffiliation': 'Beijing Chest Hospital'}}}}